Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

BPC-157 vs TB-500

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

BPC-157: CTB-500: D
AttributeBPC-157TB-500
CategoryHealing & RecoveryHealing & Recovery
Evidence RatingC — Phase I–II Clinical TrialsD — Preclinical
Clinical StatusResearch-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed.
MechanismBPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors...TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. Research in Trends in Cell Biology showed Tβ4 acts as a "battery for cell movement." It promotes angiogenesis by stim...
Half-Life~15 min IV (animal data); oral activity persists 24+ hours<2 hours plasma half-life; tissue effects persist 2–3 days
BioavailabilityIM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradationSubcutaneous injection; rapid systemic distribution
Molecular Weight~1419.5 g/mol~889 g/mol
WADA StatusProhibitedProhibited
Research Half-Life~15 min IV (animal data); oral activity persists 24+ hours<2 hours plasma half-life; tissue effects persist 2–3 days
Key Use Cases
  • Injury Recovery
  • Gut Health
  • Injury Recovery
  • Anti-Inflammatory
Safety Concerns
  • No completed randomized controlled human clinical trials for safety assessment
  • Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology
  • FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
  • A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4
  • No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike
  • Common anecdotal side effects: injection site pain/redness, lightheadedness, mild headache, nausea, fatigue
Contraindications
  • Pregnancy and breastfeeding (no safety data)
  • Active cancer or history of cancer (theoretical concern due to potent angiogenesis promotion; mechanistic overlap with tumor vascularization)
  • Individuals on anticoagulants (BPC-157 affects clotting and vessel constriction resolution)
  • Autoimmune conditions (immunogenicity risk noted by FDA)
  • Active cancer or history of cancer (research shows contrasting results — TB-500 may slow colon cancer growth by decreasing survival signal activity, but may have negative effects in other cancers)
  • Autoimmune disorders
  • Pregnancy and breastfeeding
  • Concurrent blood-thinning medications (potential interaction)
Regulatory (US)Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned.Not FDA-approved. Removed from Category 2 on April 15, 2026. PCAC review pending July 2026. Previously classified as Category 2 since September 2023. WADA-banned (S2 growth factor).

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationBPC-157TB-500
Purity Standard≥98%≥98%
CAS Number137525-51-077591-33-4
Molecular FormulaC₆₂H₉₈N₁₆O₂₂C₂₁₂H₃₅₀N₅₆O₇₈S
Available Formats5mg, 10mg, 10mg5mg, 10mg
Batch COAs Published3 on file2 on file
Stock StatusIn stockIn stock

Availability at Volta Peptides

BPC-157 5mg

≥98% purity · HPLC verified · In stock

$34

TB-500 5mg

≥98% purity · HPLC verified · In stock

$29

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.